Publicaciones en colaboración con investigadores/as de University of Manchester (131)

2024

  1. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

    Annals of Oncology, Vol. 35, Núm. 9, pp. 805-816

2023

  1. A foundation model for generalizable disease detection from retinal images

    Nature, Vol. 622, Núm. 7981, pp. 156-163

2022

  1. An aphasia research agenda–a consensus statement from the collaboration of aphasia trialists

    Aphasiology, Vol. 36, Núm. 4, pp. 555-574

  2. Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study

    Clinical Lung Cancer, Vol. 23, Núm. 8, pp. 720-730

  3. The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report

    ESMO Open, Vol. 7, Núm. 5

2021

  1. Algorithmic assessment of cellular senescence in experimental and clinical specimens

    Nature Protocols, Vol. 16, Núm. 5, pp. 2471-2498

  2. Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

    Journal of Thoracic Oncology, Vol. 16, Núm. 12, pp. 2091-2108

  3. Physiological hypoxia restrains the senescence-associated secretory phenotype via AMPK-mediated mTOR suppression

    Molecular Cell, Vol. 81, Núm. 9, pp. 2041-2052.e6

2020

  1. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

    Journal of Clinical Oncology

2019

  1. Association analyses identify 31 new risk loci for colorectal cancer susceptibility

    Nature Communications, Vol. 10, Núm. 1

  2. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

  3. Pure Membranous Lupus Nephritis: Description of a Cohort of 150 Patients and Review of the Literature

    Reumatologia Clinica, Vol. 15, Núm. 1, pp. 34-42

2018

  1. Progress of the attractiveness of Rheumatology among medical speciality training candidates (MIR) in Spain

    Reumatologia Clinica, Vol. 14, Núm. 3, pp. 150-154

  2. Sensing Uranyl(VI) Ions by Coordination and Energy Transfer to a Luminescent Europium(III) Complex

    Angewandte Chemie - International Edition, Vol. 57, Núm. 31, pp. 9921-9924

  3. Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: Results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

    Rheumatology (United Kingdom), Vol. 57, Núm. 9, pp. 1533-1540

2016

  1. Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies

    Arthritis and Rheumatology, Vol. 68, Núm. 9, pp. 2338-2344

  2. Cannabis, Endocannabinoid CB1 Receptors, and the Neuropathology of Vision

    Neuropathology of Drug Addictions and Substance Misuse (Elsevier Inc.), pp. 738-748

  3. Cannabis, Endocannabinoid CB1 Receptors, and the Neuropathology of Vision

    Neuropathology of Drug Addictions and Substance Misuse Volume 1: Foundations of Understanding, Tobacco, Alcohol, Cannabinoids and Opioids (Elsevier), pp. 738-748

  4. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  5. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222